Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOUiSSe: Remibrutinib in Moderate to Severe Sjögren's Syndrome
2018-004387-54Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of remibrutinib in Sjögren's syndrome (4 arms), sponsored by Novartis. Primary endpoint: Change from baseline in ESSDAI at Week 24. Started Apr 2019; status: terminated.
02
Drugs
remibrutinib
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2018-004387-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004387-54.